Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epithelium-on CXL in Progressive Keratoconus
NCT03442751Phase 3Completed
- Sponsor
- Glaukos Corporation
- Start
- Apr 2018
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of olmesartan medoxomil + amlodipine in keratoconus (2 arms), sponsored by Glaukos Corporation. Primary endpoint: Maximum Corneal Curvature at 6 months. Started Apr 2018; status: completed.
02
Drugs
olmesartan medoxomil + amlodipine
03
Conditions
keratoconus
Beyond the preview
Go deeper on NCT03442751.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03442751.